Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis


Current price
0.29 USD +0.0001 USD (+0.03%)
Last closed 0.33 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 487 339 USD
Yield for 12 month -92.52 %
21.11.2021 - 28.11.2021

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France. Address: Sorbonne University, Paris, France, 75005

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

150 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-803 000 USD

Last Year

-484 000 USD

Current Quarter

-653 000 USD

Last Quarter

-150 000 USD

Key Figures BPTS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -13 530 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -52.78 %
PEG Ratio
Return On Equity TTM -1244.4 %
Wall Street Target Price 150 USD
Revenue TTM
Book Value -0.005 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -3.22 USD
Diluted Eps TTM -3.22 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BPTS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BPTS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 30.03.2023
Dividend Date

Stock Valuation BPTS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -0.1897
Price Book MRQ 2.2646

Financials BPTS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BPTS

For 52 weeks

0.28 USD 4.22 USD
50 Day MA 0.44 USD
Shares Short Prior Month 42 847
200 Day MA 0.97 USD
Short Ratio 0.59
Shares Short 102 322
Short Percent 0.02 %

Dynamics of changes in the value of assets




399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds



207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics



2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics